drugset / Trial / NCT06738992

Safety and Effectiveness of Early Aspirin Administration After Mitral Valve Repair

NCT06738992

Phase 4 Recruiting 384 enrolled Guangdong Provincial People's Hospital
RandomizedParallel-groupOpen-labelPrevention

Summary

This study compares the efficacy and safety of two different antithrombotic drugs, warfarin and aspirin, in early application after mitral valve repair (MVRep). The objective is to verify whether the type of antithrombotic therapy affects clinical outcomes and the incidence of thromboembolic and bleeding complications within 3 months after MVRep, and to provide safe and effective antithrombotic treatment options for patients undergoing MVRep.

Timeline

Start
2024-11-14
Primary completion
2027-12-31
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Aspirin Small molecule 100 mg Oral
Comparator Warfarin Small molecule 4.5 mg

Indications

No indication recorded.